More on Bacterin International (BONE): Q2 beats on a per share basis while coming in-line with...

|By:, SA News Editor

More on Bacterin International (BONE): Q2 beats on a per share basis while coming in-line with revenue estimates. Total revenue grew by 9% Y/Y on higher wound care product sales, while fewer expenses and a jump in margins helped boost its bottom line. The company maintains its FY12 revenue guidance of $35M - $40M, in line, albeit at the lower end of Street estimates of $39.6M. Shares +7.8% AH.